The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis as part of a swap of more than $20 billion in assets.
via NYT > Business Day http://ift.tt/RWObui
via WordPress http://ift.tt/1jLU97R
No comments:
Post a Comment